专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016164089A3 TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF 审中-公开
标题翻译： TGF-β超级蛋白I型和II型受体异构体及其用途
公开(公告)号：WO2016164089A3
公开(公告)日：2016-12-08
申请号：PCT/US2016000033
申请日：2016-04-06
申请人： ACCELERON PHARMA INC
发明人： KUMAR RAVINDRA , GRINBERG ASYA , SAKO DIANNE S , PEARSALL ROBERT SCOTT , CASTONGUAY ROSELYNE
IPC分类号： A61K38/18 , A61K39/395 , A61P9/00 , A61P19/00 , A61P21/00 , A61P35/00 , C07K14/71 , C07K19/00
CPC分类号： C12N9/12 , A61K38/00 , A61K38/45 , C07K14/71 , C07K2319/30 , C12Y207/1103
摘要： In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK.2, ALK3, ALK4, ALK5, ALK.6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.
摘要翻译：在某些方面，本公开提供包含TGF-β家族的I型丝氨酸/苏氨酸激酶受体的细胞外结构域和TGF-β家族的II型丝氨酸/苏氨酸激酶受体的细胞外结构域的可溶性异聚多肽复合物。在一些实施方案中，本公开提供了包含选自以下的II型受体的细胞外结构域的可溶性多肽复合物：ActRIIA，ActRIIB，TGFBRII，BMPRII和MISRII。在一些实施方案中，本公开提供了包含选自以下的I型受体的细胞外结构域的可溶性多肽复合物：ALK1，ALK.2，ALK3，ALK4，ALK5，ALK.6和ALK7。任选地，可溶性复合物是异二聚体。在某些方面，这种可溶性多肽复合物可用于调节（促进或抑制）组织或细胞的生长，包括例如肌肉，骨，软骨，脂肪，神经组织，肿瘤，癌细胞和/或造血细胞谱系，包括红细胞。在某些方面，这些可溶性多肽复合物可用于改善肌肉形成，骨形成，造血，代谢参数和与这些组织，细胞网络和内分泌系统相关的病症。

2. 发明申请

WO2015077540A3 COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION 审中-公开
标题翻译：治疗肺高血压的组合物和方法
公开(公告)号：WO2015077540A3
公开(公告)日：2015-11-19
申请号：PCT/US2014066776
申请日：2014-11-21
申请人： BRIGHAM & WOMENS HOSPITAL , ACCELERON PHARMA INC
发明人： YU PAUL , GRINBERG ASYA , SAKO DIANNE S , CASTONGUAY ROSELYNE , STEEVES RITA , KUMAR RAVINDRA
IPC分类号： A61K38/00 , A61K39/00
CPC分类号： A61K38/179 , C07K14/71 , C07K2319/30
摘要： In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.
摘要翻译：在一些方面，本发明教导了包含TGF-β配体诱捕物的药物组合物，以及使用TGF-β配体诱捕器来治疗，预防或降低肺高血压（PH）的进展速率的方法。本发明还提供了使用TGF-β配体诱捕器来治疗，预防或降低多种病症的进展速率的方法，所述病症包括但不限于肺血管重塑，肺纤维化，右心室肥大，与过量相关的疾病 TGF-β信号传导，与过量的GDF15信号传导相关的疾病以及与过度的PAI-1信号传导相关的疾病。本发明进一步提供了使用TGF-β配体诱捕器降低受试者的右心室收缩压的方法。

3. 发明公开

EP3036262A4 TGF-BETA RECEPTOR TYPE II VARIANTS AND USES THEREOF 无效
标题翻译： TGF-β受体型的变异II及其用途
公开(公告)号：EP3036262A4
公开(公告)日：2017-03-01
申请号：EP14837885
申请日：2014-08-21
申请人： ACCELERON PHARMA INC
发明人： KUMAR RAVINDRA , GRINBERG ASYA , SAKO DIANNE S , CASTONGUAY ROSELYNE , STEEVES RITA
IPC分类号： C07K19/00 , A61K38/17 , A61P9/10 , A61P35/00 , C07K14/495 , C07K14/71 , C07K16/22
CPC分类号： C07K14/71 , A61K38/00 , C07K14/495 , C07K16/22 , C07K2317/76 , C07K2319/30 , C07K2319/31
摘要： In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T&bgr;RII polypeptide useful to selectively antagonize a T&bgr;RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF&bgr; associated disorders.

4. 发明公开

EP3071215A4 COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION 有权
标题翻译： ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG PULMONALER HYPERTONIE
公开(公告)号：EP3071215A4
公开(公告)日：2017-08-23
申请号：EP14864524
申请日：2014-11-21
申请人： THE BRIGHAM AND WOMEN'S HOSPITAL INC , ACCELERON PHARMA INC
发明人： YU PAUL , GRINBERG ASYA , SAKO DIANNE S , CASTONGUAY ROSELYNE , STEEVES RITA , KUMAR RAVINDRA
IPC分类号： A61K38/17 , A61K39/00 , A61P9/12 , A61P11/00 , C07K14/71 , C12N15/62
CPC分类号： A61K38/179 , C07K14/71 , C07K2319/30
摘要： In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.
摘要翻译：在一些方面，本发明教导了包含TGF-β配体诱捕物的药物组合物，以及使用TGF-β配体诱捕器来治疗，预防或降低肺高血压（PH）的进展速率的方法。本发明还提供了使用TGF-β配体诱捕器来治疗，预防或降低多种病症的进展速率的方法，所述病症包括但不限于肺血管重塑，肺纤维化，右心室肥大，与过量相关的疾病 TGF-β信号传导，与过量的GDF15信号传导相关的疾病以及与过度的PAI-1信号传导相关的疾病。本发明进一步提供了使用TGF-β配体诱捕器降低受试者的右心室收缩压的方法。

5. 发明专利

DK3685848T3 SAMMENSÆTNINGER OG FREMGANGSMÅDER TIL BEHANDLING AF PULMONAL HYPERTENSION 未知
公开(公告)号：DK3685848T3
公开(公告)日：2021-12-13
申请号：DK20150385
申请日：2014-11-21
申请人： BRIGHAM & WOMENS HOSPITAL INC , ACCELERON PHARMA INC
发明人： GRINBERG ASYA , SAKO DIANNE S , CASTONGUAY ROSELYNE , STEEVES RITA , KUMAR RAVINDRA , YU PAUL
IPC分类号： A61K38/17 , A61K39/00 , A61P9/12 , A61P11/00 , C07K14/71 , C12N15/62

6. 发明专利

SI3280727T1 Enoskupinske fuzijske beljakovine receptorjev tipa I in tipa II ter njihova uporaba 未知
公开(公告)号：SI3280727T1
公开(公告)日：2021-07-30
申请号：SI201631118
申请日：2016-04-06
申请人： ACCELERON PHARMA INC
发明人： KUMAR RAVINDRA , GRINBERG ASYA , SAKO DIANNE S
IPC分类号： A61P3/00 , A61K38/00 , A61P7/00 , A61P9/00 , A61P19/00 , A61P21/00 , A61P43/00 , C07K14/00

7. 发明专利

AU2021200906A1 Single-ARM type I and type II receptor fusion proteins and uses thereof 未知
公开(公告)号：AU2021200906A1
公开(公告)日：2021-03-04
申请号：AU2021200906
申请日：2021-02-12
申请人： ACCELERON PHARMA INC
发明人： KUMAR RAVINDRA , GRINBERG ASYA , SAKO DIANNE S
IPC分类号： C07K14/71 , A61K38/18 , A61K39/395 , A61P3/08 , A61P7/06 , A61P9/00 , A61P13/12 , A61P21/00 , C07K19/00
摘要： In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of 5 the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALKI, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. o Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used for the treatment or prevention of various TGF-beta associated conditions, including without limitation diseases and disorders associated with, for example, cancer, muscle, bone, fat, red blood cells, metabolism, fibrosis and other tissues that are affected by one or more ligands of the TGF-beta superfamily.

8. 发明专利

DK3280728T3 ALK7:ACTRIIB-HETEROMULTIMERER OG ANVENDELSER DERAF 未知
公开(公告)号：DK3280728T3
公开(公告)日：2021-03-01
申请号：DK16777229
申请日：2016-04-06
申请人： ACCELERON PHARMA INC
发明人： KNOPF JOHN , KUMAR RAVINDRA , GRINBERG ASYA , SAKO DIANNE S , PEARSALL ROBERT SCOTT , CASTONGUAY ROSELYNE , LI GANG , DAGON YOSSI
IPC分类号： A61P1/16 , A61K38/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P13/08 , A61P13/12 , A61P19/00 , A61P19/02 , A61P21/00 , A61P25/00 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , C07K14/71 , C12N9/12

9. 发明专利

AU2020281136A1 ALK7:ActRIIB heteromultimers and uses thereof 未知
公开(公告)号：AU2020281136A1
公开(公告)日：2021-01-07
申请号：AU2020281136
申请日：2020-12-04
申请人： ACCELERON PHARMA INC
发明人： KNOPF JOHN , KUMAR RAVINDRA , GRINBERG ASYA , SAKO DIANNE S , PEARSALL ROBERT SCOTT , CASTONGUAY ROSELYNE , LI GANG , DAGON YOSSI
IPC分类号： C07K14/71 , A61K38/17 , A61K39/395 , A61P3/04 , A61P13/12 , C07K19/00
摘要： ALK7:ACTRIIB HETEROMULTIMERS AND USES THEREOF In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of 5 ActRIIB. In certain aspects, these ALK7:ActRIIB heteromultimers can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.

10. 发明专利

HK1252957A1 TGF-β超家族I型和II型受體異多聚體及其用途未知
公开(公告)号：HK1252957A1
公开(公告)日：2019-06-06
申请号：HK18112314
申请日：2018-09-26
申请人： ACCELERON PHARMA INC
发明人： KUMAR RAVINDRA , GRINBERG ASYA , SAKO DIANNE S , PEARSALL ROBERT SCOTT , CASTONGUAY ROSELYNE
IPC分类号： A61P20060101 , A61K20060101 , C07K20060101

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式